Liver–Heart on chip models for drug safety
Open accessThe DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Current pre-clinical models to evaluate drug safety during the drug development process (DDP) mainly rely on traditional two-dimensional cell cultures, considered too simplistic and often ineffective, or animal experimentations, which are costly, time-consuming, and not truly representative of human responses. Their clinical translation thus remains limited, eventually causing attrition and leading to high rates of failure during clinical trials. These drawbacks can be overcome by the recently developed Organs-on-Chip (OoC) technology. OoC are sophisticated in vitro systems capable of recapitulating pivotal architecture and functionalities of human organs. OoC are receiving increasing attention from the stakeholders of the DDP, particularly concerning drug screening and safety applications. When a drug is administered in the human body, it is metabolized by the liver and the resulting compound may cause unpredicted toxicity on off-target organs such as the heart. In this sense, several liver and heart models have been widely adopted to assess the toxicity of new or recalled drugs. Recent advances in OoC technology are making available platforms encompassing multiple organs fluidically connected to efficiently assess and predict the systemic effects of compounds. Such Multi-Organs-on-Chip (MOoC) platforms represent a disruptive solution to study drug-related effects, which results particularly useful to predict liver metabolism on off-target organs to ultimately improve drug safety testing in the pre-clinical phases of the DDP. In this review, we focus on recently developed liver and heart on chip systems for drug toxicity testing. In addition, MOoC platforms encompassing connected liver and heart tissues have been further reviewed and discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging technologies, such as “organs-on-chips,” offer a dynamic and physiologically relevant platform for safety evaluations. These microfluidic devices mimic the functions of specific organs, enabling the study of systemic effects and interactions of cosmetic ingredients (142).”
From The dark side of beauty: an in-depth analysis of the health hazards and toxicological impact of synthetic cosmetics and personal care products (2024) · cites this paper as [142]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bhatia, S. N., & Ingber, D. E. (2014) · Nature Biotechnology · doi:10.1038/nbt.2989 · Cited by 3,305
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells
Si-Tayeb, K., Noto, F. K., Nagaoka, M., Li, J., Battle, M. A., Duris, C., North, P. E., Dalton, S., & Duncan, S. A. (2010) · Hepatology · doi:10.1002/hep.23354 · Cited by 1,282
Advanced maturation of human cardiac tissue grown from pluripotent stem cells
Ronaldson-Bouchard, K., Ma, S. P., Yeager, K., Chen, T., Song, L., Sirabella, D., Morikawa, K., Teles, D., Yazawa, M., & Vunjak-Novakovic, G. (2018) · Nature · doi:10.1038/s41586-018-0016-3 · Cited by 1,272
Bioprinting 3D microfibrous scaffolds for engineering endothelialized myocardium and heart-on-a-chip
Zhang, Y. S., Arneri, A., Bersini, S., Shin, S.-R., Zhu, K., Goli-Malekabadi, Z., Aleman, J., Colosi, C., Busignani, F., Dell'Erba, V., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.003 · Cited by 951
Self-citationInstrumented cardiac microphysiological devices via multimaterial three-dimensional printing
Lind, J. U., Busbee, T. A., Valentine, A. D., Pasqualini, F. S., Yuan, H., Yadid, M., Park, S.-J., Kotikian, A., Nesmith, A. P., Campbell, P. H., et al. (2017) · Nature Materials · doi:10.1038/nmat4782 · Cited by 863
Zhang, Y. S., Aleman, J., Shin, S. R., Kilic, T., Kim, D., Mousavi Shaegh, S. A., Massa, S., Riahi, R., Chae, S., Hu, N., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612906114 · Cited by 833
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Seyhan, A. A. (2019) · Translational Medicine Communications · doi:10.1186/s41231-019-0050-7 · Cited by 713
Almazroo, O. A., Miah, M. K., & Venkataramanan, R. (2017) · Clinics in Liver Disease · doi:10.1016/j.cld.2016.08.001 · Cited by 681
Research works printed but not linked: 3
- D. J. Meyer, “ The Liver,” in Canine Feline Cytology (Elsevier, 2010), Vol. 27, pp. 226– 248.
- 2016, Multi-organ toxicity demonstration in a functional human in vitro system composed of four organs, Sci. Rep., 6, 20030, 10.1002/adfm.201805792 · DOI · Paper page
- D. Lowe, “ The latest on drug failure and approval rates,” Sci. Transl. Med. 2, 14ps2 (2019).
Cited by
A Comprehensive Review of Organ-on-a-Chip Technology and Its Applications
Doost, N. F., & Srivastava, S. K. (2024) · Biosensors · doi:10.3390/bios14050225 · Cited by 187
Human organoids-on-chips for biomedical research and applications
Wang, H., Ning, X., Zhao, F. H., Zhao, H., & Li, D. (2024) · Theranostics · doi:10.7150/thno.90492 · Cited by 157
Emerging trends in organ-on-a-chip systems for drug screening
Wang, Y., Gao, Y., Pan, Y., Zhou, D., Liu, Y., Yin, Y., Yang, J., Wang, Y., & Song, Y. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.006 · Cited by 127
Advances in Spheroids and Organoids on a Chip
Fang, G., Chen, Y., Lu, H., & Jin, D. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202215043 · Cited by 141
Advances in Organ-on-a-Chip Materials and Devices
Nahak, B. K., Mishra, A., Preetam, S., & Tiwari, A. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00041 · Cited by 134
Metadata
- Authors
- Ferrari, E., & Rasponi, M.
- Affiliations
- Politecnico di Milano (IT)
- Corresponding author
- Rasponi, Marco
- Venue
- APL Bioengineering
- Publisher
- AIP Publishing
- Published
- 2021-07-14
- Volume
- 5
- Issue
- 3
- Pages
- 031505-031505
- ISSN
- 2473-2877 (ISSN-L)
- PMC
- PMC8282347
- OpenAlex
- W3180743733
- Cited by
- 53
- References
- 116
- Citations by year
- 2026: 14 · 2025: 6 · 2024: 14 · 2023: 12 · 2022: 6 · 2021: 1
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- APL Bioengineering (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Virtual Community of Pathological Anatomy (University of Castilla La Mancha) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Italian Ministry of Health (GR-2016-02364990)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- organ-on-a-chip, liver-on-a-chip, drug safety testing, drug toxicity, drug metabolism, off-target toxicity, drug development, in vitro model, drug attrition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liver–Heart on chip models for drug safety. https://app.cochat.ai/papers/10.1063/5.0048986
- The paper
- Ferrari, E., & Rasponi, M. (2021). Liver–Heart on chip models for drug safety. APL Bioengineering. https://doi.org/10.1063/5.0048986
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.